SK Biopharmaceuticals Co., Ltd. (326030.KS)
KRW 103600.0
(-2.54%)
KRW 103600.0
(-2.54%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -37.52 Billion KRW | 71.37% |
| 2022 | -131.07 Billion KRW | -276.54% |
| 2021 | 74.24 Billion KRW | 131.0% |
| 2020 | -239.49 Billion KRW | -202.17% |
| 2019 | -79.25 Billion KRW | 43.02% |
| 2018 | -139.1 Billion KRW | -41.98% |
| 2017 | -97.97 Billion KRW | -69.88% |
| 2016 | -57.67 Billion KRW | -46.22% |
| 2015 | -39.44 Billion KRW | -0.52% |
| 2014 | -39.23 Billion KRW | 11.14% |
| 2013 | -44.15 Billion KRW | -22.69% |
| 2012 | -35.99 Billion KRW | -48.06% |
| 2011 | -24.3 Billion KRW | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | 26.04 Billion KRW | 153.98% |
| 2024 Q1 | 10.25 Billion KRW | -30.63% |
| 2023 Q1 | 2.72 Billion KRW | 106.1% |
| 2023 Q3 | -10.71 Billion KRW | 43.43% |
| 2023 Q2 | -18.93 Billion KRW | -795.46% |
| 2023 FY | -37.52 Billion KRW | 71.37% |
| 2023 Q4 | 14.78 Billion KRW | 238.0% |
| 2022 FY | -131.07 Billion KRW | -276.54% |
| 2022 Q4 | -44.62 Billion KRW | -382.52% |
| 2022 Q3 | -9.24 Billion KRW | 76.92% |
| 2022 Q2 | -40.07 Billion KRW | -7.9% |
| 2022 Q1 | -37.13 Billion KRW | -127.71% |
| 2021 FY | 74.24 Billion KRW | 131.0% |
| 2021 Q4 | 134.04 Billion KRW | 368.42% |
| 2021 Q2 | -65.08 Billion KRW | -185.71% |
| 2021 Q3 | -49.93 Billion KRW | 23.27% |
| 2021 Q1 | 75.93 Billion KRW | 241.9% |
| 2020 FY | -239.49 Billion KRW | -202.17% |
| 2020 Q4 | -53.5 Billion KRW | 15.11% |
| 2020 Q2 | -57.83 Billion KRW | 11.18% |
| 2020 Q1 | -65.11 Billion KRW | 1.37% |
| 2020 Q3 | -63.03 Billion KRW | -8.99% |
| 2019 Q4 | -66.02 Billion KRW | -30.76% |
| 2019 FY | -79.25 Billion KRW | 43.02% |
| 2019 Q3 | -50.49 Billion KRW | -31.46% |
| 2019 Q2 | -38.4 Billion KRW | -150.76% |
| 2019 Q1 | 75.66 Billion KRW | 0.0% |
| 2018 FY | -139.1 Billion KRW | -41.98% |
| 2017 FY | -97.97 Billion KRW | -69.88% |
| 2016 FY | -57.67 Billion KRW | -46.22% |
| 2015 FY | -39.44 Billion KRW | -0.52% |
| 2014 FY | -39.23 Billion KRW | 11.14% |
| 2013 FY | -44.15 Billion KRW | -22.69% |
| 2012 FY | -35.99 Billion KRW | -48.06% |
| 2011 FY | -24.3 Billion KRW | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| ORIENT BIO Inc. | 1.45 Billion KRW | 2682.733% |
| Green Cross Holdings Corporation | -16.43 Billion KRW | -128.266% |
| Green Cross Holdings Corporation | 34.43 Billion KRW | 208.962% |
| Pharmicell Co., Ltd. | 950.99 Million KRW | 4045.566% |
| Green Cross Corporation | 34.43 Billion KRW | 208.962% |
| GeneOne Life Science, Inc. | -48.36 Billion KRW | 22.424% |
| Celltrion, Inc. | 651.43 Billion KRW | 105.76% |
| Samsung Biologics Co.,Ltd. | 1155.98 Billion KRW | 103.246% |
| SK bioscience Co.,Ltd. | -4.73 Billion KRW | -693.115% |
| Prestige BioPharma Limited | -62.78 Billion KRW | 40.235% |